Red Orbit (Free subscription) | 05/15/2008
More than 100 scientific abstracts on six Bristol-Myers Squibb Company (NYSE:BMY) oncology compounds will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30- June 2.
Business Wire (Free subscription) | 05/15/2008
PRINCETON, N.J.--(BUSINESS WIRE)--More than 100 scientific abstracts on six Bristol-Myers Squibb Company (NYSE:BMY) oncology compounds
Jim Cramer's Mad Money (Free subscription) | 05/15/2008
Jim Cramer’s Mad Money Stock Picks for Wednesday May 14 2008. These are all of Jim Cramer’s stock picks that are a Buy! I bold my picks. Buy: ALCOA (AA) Apache (APA) Bristol-Myers Squibb (BMY) Caterpillar (CAT) DuPont (DD) Diamond Offshore (DO) Devon Energy (DVN) Fortune Brands (FO) First Solar (FSLR) Goldman Sachs (GS) HJ Heinz (HNZ) Honeywell (HON) Precision Castparts (PCP) Woodward Governor...
The San Francisco Business Times (Free subscription) | 05/13/2008
Bristol-Myers Squibb Co. will pay $25 million up front to Kai Pharmaceuticals for the right to develop a heart attack drug. (BMY)
Reuters UK (Free subscription) | 05/13/2008
NEW YORK (Reuters) - Bristol-Myers Squibb Co has struck a deal to develop KAI Pharmaceuticals' experimental medicine for lessening the impact of heart attacks, the companies said on Tuesday.
bizjournals (Free subscription) | 05/13/2008
Kai Pharmaceuticals Inc. and Bristol-Myers Squibb Co. said Tuesday they entered a pact for global development and commercialization of KAI-9803, which is designed to help reduce the size and effect of heart attack. (BMY)
Reuters (Free subscription) | 05/13/2008
NEW YORK (Reuters) - Bristol-Myers Squibb Co has struck a deal to develop KAI Pharmaceuticals' experimental medicine for lessening the impact of heart attacks, the companies said on Tuesday.
Business Wire (Free subscription) | 05/13/2008
PRINCETON, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and KAI Pharmaceuticals, Inc., a privately held biotechnology company, today announced an
Pharmalot (Free subscription) | 05/13/2008
A funny thing happened on the way to the US Supreme Court this week - a few justices had to recuse themselves from a case because they held stock in companies with a matter before the court. Justice Samuel Alito, for instance, holds shares in Bristol-Myers Squibb. This was the second recent instance in which a [...]
Fiercebiotech (Free subscription) | 05/13/2008
South San Francisco-based KAI Pharmaceuticals is getting a $25 million boost from Bristol-Myers Squibb---its upfront payment for a collaboration on KAI-9803, an experimental therapy to reduce the Read more...
Pharmalot (Free subscription) | 05/12/2008
The US Supreme Court can't intervene in an important dispute over the rights of apartheid victims to sue US corporations in US courts because four of the nine justices had to sit out the case over apparent conflicts, including stockholdings in Bristol-Myers Squibb, the Associated Press writes. The result is that a lawsuit accusing some prominent [...]
Inbox Robot: Swiss Reinsurance News (Free subscription) | 05/11/2008
The blitzkrieg has begun on Sanofi-Aventis and American partner Bristol-Myers Squibb , as the patents on their blockbuster blood-thinner Plavix are being threatened
Inbox Robot: Swiss Reinsurance News (Free subscription) | 05/09/2008
Bristol Myers Squibb NewsBite - BMY to Face Generic Competition in Europe Posted on Friday, May 09, 2008 12:52 PM opened at 22.15. So
Market Watch (Free subscription) | 05/09/2008
Drug stocks trade lower, with Mylan shares particularly weak and with Bristol-Myers Squibb and Sanofi-Aventis losing ground over jitters tied to a rival's plan to launch a generic version of Plavix in Europe.
Market Watch (Free subscription) | 05/09/2008
BOSTON (MarketWatch) -- Drug stocks followed the broader market lower early Friday as shares of Plavix makers Bristol-Myers Squibb and Sanofi-Aventis lost ground on news that Swiss drugmaker Schweizerhill Holdings AG was seeking to put out a generic version of the drug in Europe. The Amex Pharmaceutical Index slid 0.9% to 297.3 and the Amex Biotechnology Index fell 1% to 740.3. Bristol-Myers...
